U.S. FDA advisers to review Merck’s oral COVID-19 drug next month

Stock Markets7 minutes ago (Oct 14, 2021 02:37PM ET)

(C) Reuters. FILE PHOTO: FILE PHOTO: The Merck logo is seen at a gate to the Merck & Co campus in Rahway, New Jersey, U.S., July 12, 2018. REUTERS/Brendan McDermid

(Reuters) -A panel of outside advisers to the U.S. health regulator will meet late next month to discuss whether to authorize Merck & Co’s experimental COVID-19 antiviral drug, the agency said on Thursday.

The U.S. Food and Drug Administration’s (FDA) panel will meet on Nov. 30 to discuss safety and effectiveness of the drug, molnupiravir, for the treatment of mild-to-moderate COVID-19 in adults who have tested positive and are at high risk for progression to severe illness. (https://refini.tv/3p1PETq)

The FDA typically follows the advice of its experts but is not bound to do so.

Merck earlier this week said it filed for U.S. emergency use authorization for molnupiravir, which it is developing with partner Ridgeback Biotherapeutics. The drug would become the first oral antiviral medication for COVID-19, if cleared by the agency.

Pfizer Inc (NYSE:PFE) and Swiss drugmaker Roche Holding AG (OTC:RHHVF) are also racing to develop an easy-to-administer antiviral pill for the disease.

Merck’s treatment cut the rate of hospitalization and death by 50% in a trial of mild-to-moderately ill patients who had at least one risk factor for the disease, according to data released earlier this month.

The company has a contract with the U.S. government to supply 1.7 million courses at a price of $700 per course. The drugmaker also recently signed deals with Malaysia and Singapore for supply of the drug.

Bloomberg News first reported on a U.S. FDA advisory committee review of the drug.

U.S. FDA advisers to review Merck’s oral COVID-19 drug next month

Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn`t bear any responsibility for any trading losses you might incur as a result of using this data.

Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.

More from author


Related posts

Latest posts

U.S. surgeons successfully test pig kidney transplant in human patient

Stock Markets9 minutes ago (Oct 19, 2021 07:11PM ET) (C) Reuters. By Nancy Lapid NEW YORK (Reuters) - For the first time, a pig kidney...

Haiti gang seeks $1 million per person for kidnapped missionaries

World29 minutes ago (Oct 19, 2021 06:50PM ET) (C) Reuters. An entrance to the Christian Aid Ministries compound is seen after the abduction of a...

U.S. House committee nears contempt vote on Trump aide Bannon

World18 minutes ago (Oct 19, 2021 07:01PM ET) (C) Reuters. FILE PHOTO: Former White House Chief Strategist Steve Bannon exits the Manhattan Federal Court, following...


Want to stay up to date with the latest news?

We would love to hear from you! Please fill in your details and we will stay in touch. It's that simple!